bluebird bio, Inc. (NASDAQ:BLUE) – Oppenheimer issued their Q4 2017 EPS estimates for shares of bluebird bio in a research note issued on Wednesday. Oppenheimer analyst M. Breidenbach forecasts that the biotechnology company will post earnings of ($1.79) per share for the quarter. Oppenheimer has a “Market Perform” rating on the stock. Oppenheimer also issued estimates for bluebird bio’s Q1 2018 earnings at ($1.70) EPS, Q2 2018 earnings at ($1.73) EPS, Q3 2018 earnings at ($1.77) EPS, Q1 2019 earnings at ($1.96) EPS, Q2 2019 earnings at ($2.10) EPS, Q3 2019 earnings at ($1.71) EPS, FY2020 earnings at ($2.06) EPS and FY2021 earnings at $0.64 EPS.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business had revenue of $7.71 million for the quarter, compared to analysts’ expectations of $8.47 million. During the same quarter last year, the business posted ($2.07) earnings per share. The business’s revenue was up 397.4% compared to the same quarter last year.

A number of other brokerages also recently commented on BLUE. Maxim Group reiterated a “buy” rating and set a $170.00 price target (up from $100.00) on shares of bluebird bio in a report on Monday, October 9th. Barclays began coverage on shares of bluebird bio in a report on Wednesday, September 6th. They issued an “overweight” rating and a $151.00 target price for the company. Wedbush restated an “outperform” rating and issued a $135.00 target price (up from $121.00) on shares of bluebird bio in a report on Friday, September 1st. Leerink Swann restated an “outperform” rating and issued a $162.00 target price (up from $145.00) on shares of bluebird bio in a report on Wednesday, November 1st. Finally, BMO Capital Markets boosted their target price on shares of bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a report on Monday, October 30th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the company. bluebird bio presently has an average rating of “Hold” and a consensus price target of $157.45.

Shares of bluebird bio (BLUE) opened at $179.55 on Friday. The company has a market cap of $7,970.00, a PE ratio of -25.61 and a beta of 2.08. bluebird bio has a twelve month low of $60.95 and a twelve month high of $222.03.

A number of hedge funds have recently bought and sold shares of BLUE. Hanseatic Management Services Inc. lifted its holdings in bluebird bio by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock valued at $1,096,000 after acquiring an additional 27 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in bluebird bio by 1.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock valued at $341,000 after acquiring an additional 53 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its holdings in bluebird bio by 0.8% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock valued at $1,885,000 after acquiring an additional 140 shares during the last quarter. Prudential Financial Inc. lifted its holdings in bluebird bio by 4.0% in the 2nd quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 150 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in bluebird bio by 0.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock valued at $3,302,000 after acquiring an additional 151 shares during the last quarter.

In other news, insider Nick Leschly sold 117,500 shares of the company’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $184.08, for a total transaction of $21,629,400.00. Following the completion of the transaction, the insider now owns 293,232 shares in the company, valued at $53,978,146.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Susanna Gatti High sold 1,282 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $172.15, for a total transaction of $220,696.30. Following the transaction, the chief operating officer now owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 215,082 shares of company stock valued at $37,227,332. 3.90% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This news story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://theolympiareport.com/2017/12/24/analysts-offer-predictions-for-bluebird-bio-inc-s-q4-2017-earnings-blue.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.